Researchers at the Department of Obstetrics and Gynecology of the Medical Center — University of Freiburg have developed an approach for detecting breast cancer by means of urine samples that is highly accurate
The method involves determining the concentration of molecules that regulate cell metabolism and that are often dysregulated in cancer cells. These molecules, referred to as microRNAs, enter into the urine over the blood. By determining the composition of microRNAs in the urine, the scientists succeeded in establishing with 91 percent accuracy whether a test subject was healthy or diseased.
The measurement was possible through the detection of only four microRNAs. If the effectiveness of the method is confirmed in further studies, it could serve in the future as a means of monitoring the success of treatment and potentially also of making an early diagnosis of breast cancer.
The Freiburg scientists published their findings in the journal BMC Cancer and have applied for a patent for the method.
About 1.7 million women suffer from breast cancer worldwide. It is the most common type of tumor in women. The disease claims more than 520 thousand lives each year. Up to now, doctors have made the diagnosis by mammography or ultrasound and confirmed it with tissue samples. However, these methods have been subject to recurring criticism due to radiation exposure, erroneous results, and the fact that they involve an invasive intervention.
Experimental test already highly accurate
Prof. Dr. Elmar Stickeler, medical director of Senology at the Department of Obstetrics and Gynecology and head of the Breast Center at the Medical Center — University of Freiburg, and his team have now developed a urine test capable of detecting tumors on the basis of changes in metabolism. The researchers measured the concentrations of nine microRNAs in the urine, short genetic sequences that regulate cell metabolism. Four of the nine molecules exhibited significant differences in concentration between healthy and diseased test subjects.
“We discovered that the microRNA profile in the urine is modified in a characteristic way in the urine of test subjects with breast cancer,” says Prof. Stickeler. “MicroRNAs should thus be suitable in principle for a breast cancer test.” With the help of the microRNA profiles, the researchers were able to determine with 91 percent accuracy whether a test subject was healthy or diseased. “Our method therefore led to highly accurate diagnoses,” says Prof. Stickeler.
The study included 24 healthy test subjects and 24 women who had recently been diagnosed with a breast tumor. The patients were in tumor stages 1, 2, or 3. It will now be necessary to conduct further studies to confirm the effectiveness of the method with larger groups of patients.
The Latest on: Breast Cancer
via Google News
The Latest on: Breast Cancer
- Colon cancer screenings increase when Medicaid arrives on May 25, 2019 at 8:08 am
RELATED Aspirin could prevent colon cancer but too few people take it The report also found that breast cancer screening increased only modestly among low-income women in the states that expanded ... […]
- Running is treatment for Long Beach woman with stage 4 breast cancer on May 25, 2019 at 3:00 am
There are days when the pain from Renee Seman’s breast cancer is so severe that she can’t get out of bed. But on April 28, the Long Beach woman crossed the finish line of the London Marathon, ... […]
- Breast cancer survivor throws out first pitch at Bats game after son's letter to team on May 24, 2019 at 8:26 pm
LOUISVILLE, Ky. — One mother was honored at a Louisville Bats game after her son's letter touched the heartstrings of the team's vice president. Ty Westerman called his mother Sara a "survivor" in his ... […]
- First PI3K Inhibitor Wins FDA Approval in Breast Cancer on May 24, 2019 at 2:39 pm
WASHINGTON -- The FDA approved the first PI3K inhibitor for breast cancer. Alpelisib (Piqray) received approval for use in combination with the hormonal agent fulvestrant (Faslodex) to treat advanced, ... […]
- Doctors Need To Know More About Breast Density For Breast Cancer Screening, Researchers Say on May 24, 2019 at 2:12 pm
On your next mammogram visit, you should ask your healthcare provider about your breast density, researchers suggest. Their objective in a study, published in the peer-reviewed Journal of Women’s ... […]
- FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer on May 24, 2019 at 2:02 pm
Piqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant ... […]
- Novartis gets FDA nod for advanced breast-cancer treatment on May 24, 2019 at 1:44 pm
Novartis AG NVS, +3.65% said late Friday the U.S. Food and Drug Administration has approved one of its treatments for a type of advanced breast cancer afflicting patients carrying a gene mutation. The ... […]
- FDA OKs Novartis' alpelisib for certain type of breast cancer; shares up 4% on May 24, 2019 at 12:59 pm
The FDA approves Novartis' (NVS +3.7%) Piqray (alpelisib), a PI3K inhibitor, for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative PIK3CA ... […]
- Novartis' breast cancer treatment wins FDA approval on May 24, 2019 at 12:46 pm
(Reuters) - The U.S. Food and Drug Administration (FDA) said on Friday that it had approved Novartis AG’s treatment in combination with a hormone therapy for postmenopausal women, as well as for men, ... […]
- BRIEF-FDA Approves Novartis' Piqray, the First Pi3k Inhibitor For Breast Cancer on May 24, 2019 at 12:08 pm
* FDA- ALSO APPROVED COMPANION DIAGNOSTIC TEST, THERASCREEN PIK3CA RGQ PCR KIT, TO DETECT PIK3CA MUTATION IN A TISSUE AND/OR A LIQUID BIOPSY Source text for Eikon: Further company coverage: Our ... […]
via Bing News